aTYR PHARMA (ATYR) Non-Current Debt (2014 - 2019)

aTYR PHARMA (ATYR) has reported Non-Current Debt for 6 consecutive years, with $2.7 million the latest figure, recorded in Q3 2019.

• For the quarter ending Q3 2019, Non-Current Debt fell 72.76% year-over-year to $2.7 million; the trailing twelve-month figure through Sep 2019 stood at $2.7 million (down 72.76% YoY), and the FY2018 full-year result was $8.3 million, down 43.86% from the prior year.
• Non-Current Debt declined to $2.7 million in Q3 2019 per ATYR's latest filing, from $4.6 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $14.7 million in Q4 2017 and bottomed at $896000.0 in Q1 2016.
• Historically, Non-Current Debt has averaged $7.5 million across 5 years, with a median of $8.3 million in 2018.
• The sharpest annual moves came in 2016 and 2017: Non-Current Debt sank 79.27% in 2016, then soared 846.43% in 2017.
• Over 5 years, Non-Current Debt stood at $1.8 million in 2015, then jumped by 417.91% to $9.2 million in 2016, then soared by 60.02% to $14.7 million in 2017, then slumped by 43.86% to $8.3 million in 2018, then slumped by 66.82% to $2.7 million in 2019.
• According to Business Quant data, Non-Current Debt over the past three periods registered $2.7 million, $4.6 million, and $6.4 million for Q3 2019, Q2 2019, and Q1 2019 respectively.